Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.

The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.

Waskyra, developed by Fondazione Telethon, is the first gene therapy that the FDA has approved from a non-profit applicant.